<DOC>
	<DOC>NCT01544296</DOC>
	<brief_summary>This is a placebo-controlled, double blind, crossover study to evaluate the efficacy and safety of KHK6188 in postherpetic neuralgia when administered orally for 2 weeks.</brief_summary>
	<brief_title>A Comparative Study of KHK6188</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia, Postherpetic</mesh_term>
	<criteria>Patients with pain for ≥ 3 months and ≤ 1 year following onset of a herpes zoster rash Patients with a mean pain intensity score (11point numerical rating scale) of ≥ 4 Patients whose rash has been healed Patients who are able to fill their patient diary Patients who provided written voluntary informed consent to participate in the study Patients who have other pain or disease which may impair the self assessment of pain Patients who have dementia, depression or schizophrenia which may affect the self assessment of pain History or presence of severe cardiovascular disease, hepatic dysfunction, renal failure, respiratory disease, blood disease or CNS disorder History or presence of a drug allergy Patients who have a history of a diagnosis of cancer or a treatment of cancer within 5 years prior to the study entry Patients received an investigational medication within 4 months (6 months for biologic medication such as antibody) prior to the informed consent Women of child bearing potential who do not agree to avoid pregnancy from the time of providing the consent until 3 months after the end of dosing, or men of reproductive potential who do not agree to avoid pregnancy from the time of the first dose until 3 months after the end of dosing Patients who are pregnant, lactating, or possibly pregnant Patients judged to be inappropriate to enter the study by a investigator or a subinvestigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
</DOC>